Melanoma holds the largest share of the mRNA cancer vaccine market, driven by breakthrough therapy designations and compelling phase 2b data from Moderna and Merck's mRNA-4157/V940 combination with Keytruda — demonstrating a 44% reduction in recurrence risk. The melanoma segment was valued at $1.5 billion in 2024 and is projected to reach $8.5 billion by 2035, reflecting the...
จองคิวบริการ
NR tours
Youplay
NR shop
NR jobs
facebook th
